{
    "clinical_study": {
        "@rank": "63685", 
        "arm_group": {
            "arm_group_label": "Alemtuzumab, antibody", 
            "arm_group_type": "Experimental", 
            "description": "alemtuzumab - anti CD 52 antibody administered as consolidation, total dose 133 mg"
        }, 
        "brief_summary": {
            "textblock": "Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus\n      PEG-Filgrastim Followed by Alemtuzumab Consolidation"
        }, 
        "brief_title": "CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma", 
        "completion_date": {
            "#text": "February 2011", 
            "@type": "Actual"
        }, 
        "condition": "Peripheral T-Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Peripheral"
            ]
        }, 
        "detailed_description": {
            "textblock": "Peripheral T cell lymphoma patients of all subtypes according to WHO are treated with an\n      induction of 6 cycles of CHOP-etoposide-14 (if below 60 years of age) oder CHOP-14. If at\n      least a PR is reached, consolidation with alemtuzumab, total dose 133 mg, is given i.v."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  all risk groups in international prognostic index\n\n          -  diagnosis of aggressive T-cell-lymphoma, confirmed by an excisional biopsy of a lymph\n             node or by sufficiently extensive biopsy of an extranodal involvment, if there is no\n             lymph node involvment.\n\n          -  these lymphomas comprise: peripheral T-cell lymphoma PTCL-NOS Lennert\u00b4s lymphoma\n             T-zone lymphoma angioimmunoblastic T-cell-lymphoma\n\n          -  Performance status: ECOG (Eastern Cooperative Oncology Group Score) 0-3(Karnofsky\n             index 40-100%)\n\n          -  written consent of the patient\n\n          -  Declaration of center participation\n\n        Exclusion Criteria:\n\n          -  Already initiated lymphoma therapy(exept for the prephase treatment specified for\n             this study)\n\n          -  Serious accompanying disorder or impaired organ function\n\n          -  bone marrow involvement>25%\n\n          -  Known hypersensitivity to medications to be used\n\n          -  Know HIV-positivity\n\n          -  Active hepatitis infection, active CMV infection, prior florid tuberculosis\n\n          -  floride systemic infections\n\n          -  suspicion that patient compliance will be poor\n\n          -  Simultaneous participation in any the study protocol\n\n          -  prior chemo-or radiotherapy for malignancy\n\n          -  other concomitant malignant disease\n\n          -  Pregnancy or lactation period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806337", 
            "org_study_id": "DSHNHL-2003-1", 
            "secondary_id": "German High Grade Lymphoma SG"
        }, 
        "intervention": {
            "arm_group_label": "Alemtuzumab, antibody", 
            "description": "Consolidation after CHOP induction", 
            "intervention_name": "Alemtuzumab", 
            "intervention_type": "Drug", 
            "other_name": "MabCampath"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Alemtuzumab", 
                "Campath 1G", 
                "Antibodies, Neoplasm"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "peripheral T cell lymphoma", 
            "alemtuzumab", 
            "consolidation"
        ], 
        "lastchanged_date": "March 6, 2013", 
        "number_of_arms": "1", 
        "official_title": "Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation", 
        "overall_official": {
            "affiliation": "German High Grade Non Hodgkin\u00b4s Lymphoma Study Group", 
            "last_name": "Lorenz Truemper", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "A descriptive approach for the primary endpoint was chosen: Adherence to schedule of alemtuzumab consolidation (number of cycles, dosing, time) - comparison of planned vs given in pts receiving alemtuzumab", 
            "measure": "Feasibility of alemtuzumab consolidation after CHO(E)P 14 induction chemotherapy", 
            "safety_issue": "Yes", 
            "time_frame": "average of 24 weeks (treatment duration)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806337"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of G\u00f6ttingen", 
            "investigator_full_name": "Lorenz, Tr\u00fcmper, MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "rate of complete remissions", 
                "safety_issue": "No", 
                "time_frame": "at week 24 after initiation"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "University of G\u00f6ttingen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of G\u00f6ttingen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2003", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}